DK3446565T3 - Fremgangsmåder til behandling af antipsykotika-induceret vægtøgning - Google Patents

Fremgangsmåder til behandling af antipsykotika-induceret vægtøgning Download PDF

Info

Publication number
DK3446565T3
DK3446565T3 DK18198977.3T DK18198977T DK3446565T3 DK 3446565 T3 DK3446565 T3 DK 3446565T3 DK 18198977 T DK18198977 T DK 18198977T DK 3446565 T3 DK3446565 T3 DK 3446565T3
Authority
DK
Denmark
Prior art keywords
antipsychotic
approaches
treatment
weight gain
induced weight
Prior art date
Application number
DK18198977.3T
Other languages
English (en)
Inventor
Daniel Deaver
Mark Todtenkopf
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45723770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3446565(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Application granted granted Critical
Publication of DK3446565T3 publication Critical patent/DK3446565T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DK18198977.3T 2010-08-23 2011-08-23 Fremgangsmåder til behandling af antipsykotika-induceret vægtøgning DK3446565T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37612010P 2010-08-23 2010-08-23
EP11820517.8A EP2608670B1 (en) 2010-08-23 2011-08-23 Methods for treating antipsychotic-induced weight gain

Publications (1)

Publication Number Publication Date
DK3446565T3 true DK3446565T3 (da) 2024-01-22

Family

ID=45723770

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18198977.3T DK3446565T3 (da) 2010-08-23 2011-08-23 Fremgangsmåder til behandling af antipsykotika-induceret vægtøgning
DK11820517.8T DK2608670T3 (da) 2010-08-23 2011-08-23 Fremgangsmåde til behandling af antipsykotikum-induceret vægtstigning

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11820517.8T DK2608670T3 (da) 2010-08-23 2011-08-23 Fremgangsmåde til behandling af antipsykotikum-induceret vægtstigning

Country Status (20)

Country Link
US (11) US8778960B2 (da)
EP (3) EP2608670B1 (da)
JP (1) JP5684388B2 (da)
AU (4) AU2011293502B2 (da)
CA (1) CA2807965C (da)
CY (1) CY1121128T1 (da)
DK (2) DK3446565T3 (da)
ES (2) ES2969625T3 (da)
FI (1) FI3446565T3 (da)
HR (2) HRP20240109T1 (da)
HU (2) HUE041981T2 (da)
LT (2) LT3446565T (da)
NZ (1) NZ606730A (da)
PL (2) PL3446565T3 (da)
PT (2) PT3446565T (da)
RS (2) RS58312B1 (da)
SI (2) SI2608670T1 (da)
SM (2) SMT201900051T1 (da)
TR (1) TR201900097T4 (da)
WO (1) WO2012027359A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2445502T (pt) * 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
HUE043963T2 (hu) 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
EP2608670B1 (en) 2010-08-23 2018-10-31 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
WO2020006367A1 (en) * 2018-06-29 2020-01-02 Tufts Medical Center, Inc. Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
US20250186324A1 (en) 2022-06-17 2025-06-12 Mesoestetic Pharma Group, S.L Synergistic skin depigmenting cosmetic composition

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES252980A1 (es) 1958-10-30 1960-11-01 Boehringer Sohn Ingelheim Procedimiento para la obtencion de nuevas sales cuaternarias, terapéuticamente valiosas, de la normorfina y de sus derivados
GB981046A (en) 1962-07-02 1965-01-20 British Drug Houses Ltd Hexahydro-4ah-8,9c-iminoethano phenanthro-[4,5-b,c,d]-furan derivatives
BE634402A (fr) 1962-07-02 1964-01-02 British Drug Houses Ltd Dérivés de l'hydrophénanthrène et leurs procédés de préparation
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CH581624A5 (da) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
DE2254298A1 (de) 1972-11-06 1974-05-16 Boehringer Sohn Ingelheim Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4161597A (en) 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives
US4100228A (en) 1977-04-04 1978-07-11 The Dow Chemical Company Transparent impact styrene polymer structure
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
FR2514644A1 (fr) 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
DE3220831A1 (de) 1982-06-03 1983-12-08 Boehringer Ingelheim KG, 6507 Ingelheim N-(2-methoxyethyl)-noroxymorphon, dessen saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US4929622A (en) 1987-09-24 1990-05-29 Hoechst-Roussel Pharmaceuticals, Inc. 2,6-Methanopyrrolo-3-benzazocines
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
JPH05231100A (ja) 1992-02-25 1993-09-07 Hazama Gumi Ltd トンネル用通気仕切り
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
ATE212830T1 (de) 1993-11-19 2002-02-15 Alkermes Inc Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
HUP9900974A3 (en) 1996-01-10 2000-09-28 Smithkline Beecham Spa Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
GB9616253D0 (en) 1996-08-01 1996-09-11 Johnson Matthey Plc Preparation of narcotic analgesics
ES2121553B1 (es) 1996-12-23 1999-06-16 Univ Santiago Compostela Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion.
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
WO2001012197A1 (en) 1999-08-13 2001-02-22 Southern Research Institute Pyridomorphinans, thienomoprhinans and use thereof
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
EP1244447B1 (en) 1999-11-29 2007-01-10 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
ATE292625T1 (de) 2000-10-31 2005-04-15 Rensselaer Polytech Inst 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
PT1485051E (pt) 2002-03-20 2008-07-09 Euro Celtique Sa Processo de administração da buprenorfina para o tratamento da depressão
WO2003101963A1 (en) 2002-05-30 2003-12-11 Eli Lilly And Company Opioid receptor antagonists
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
WO2004007449A1 (en) 2002-07-16 2004-01-22 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
AU2003298691A1 (en) 2002-11-18 2004-06-15 The Mclean Hospital Corporation Mixed kappa/mu opioids and uses thereof
US20040192715A1 (en) 2003-02-05 2004-09-30 Mark Chasin Methods of administering opioid antagonists and compositions thereof
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
CA2553309A1 (en) 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
MXPA06013270A (es) 2004-05-14 2007-04-23 Johnson & Johnson Compuestos de opioide carboxamido.
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7262298B2 (en) 2004-11-05 2007-08-28 Rensselaer Polytechnic Institute 4-hydroxybenzomorphans
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
AU2006272773B2 (en) 2005-07-21 2012-03-08 Rensselaer Polytechnic Institute 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
EP1983991A2 (en) 2006-02-01 2008-10-29 Alkermes, Inc. Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
EP2099764B1 (en) 2006-09-20 2011-07-27 Mallinckrodt Inc. Preparation of substituted morphinan-6-ones and salts and intermediates thereof
DK2073636T3 (da) 2006-10-17 2012-11-19 Penick Corp Fremgangsmåde til fremstilling af oxymorphon
US20080234306A1 (en) 2006-11-22 2008-09-25 Progenics Pharmaceuticals, Inc. N-Oxides of 4,5-Epoxy-Morphinanium Analogs
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
US20100130512A1 (en) 2007-05-16 2010-05-27 Rensselaer Polytechnic Institute Fused-ring heterocycle opioids
WO2009009083A1 (en) 2007-07-12 2009-01-15 The Mclean Hospital Corporation R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof
WO2009023567A1 (en) 2007-08-09 2009-02-19 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
JP2011512360A (ja) 2008-02-14 2011-04-21 アルカーメス，インコーポレイテッド 選択的オピオイド化合物
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US20100190817A1 (en) 2008-07-21 2010-07-29 Rensselaer Polytechnic Institute Large substituent, non-phenolic amine opioids
WO2010107457A1 (en) 2009-03-19 2010-09-23 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
US20120149724A1 (en) 2009-06-04 2012-06-14 The General Hospital Corporation Modulating endogenous beta-endorphin levels
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
HUE043963T2 (hu) 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
WO2011119605A2 (en) 2010-03-22 2011-09-29 Rensselaer Polytechnic Institute Carboxamide biosiosteres of opiates
WO2012005795A1 (en) 2010-07-08 2012-01-12 Alkermes, Inc. Process for the synthesis of substituted morphinans
ES2470315T3 (es) 2010-08-04 2014-06-23 Mallinckrodt Llc N-desmetilaci�n de 6-ceto morfinanos
EP2608670B1 (en) * 2010-08-23 2018-10-31 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US8987293B2 (en) 2010-12-23 2015-03-24 Phoenix Pharmalabs, Inc. Morphinans useful as analgesics
SMT201800664T1 (it) 2011-12-15 2019-01-11 Alkermes Pharma Ireland Ltd Samidorphan (alks 33) in combinazione con buprenorfina per il trattamento di disturbi depressivi
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms

Also Published As

Publication number Publication date
DK2608670T3 (da) 2019-02-11
FI3446565T3 (fi) 2024-01-30
RS65091B1 (sr) 2024-02-29
US10716785B2 (en) 2020-07-21
NZ606730A (en) 2015-05-29
EP2608670A4 (en) 2014-05-07
RS58312B1 (sr) 2019-03-29
PT2608670T (pt) 2019-02-01
JP2013536239A (ja) 2013-09-19
LT3446565T (lt) 2024-01-10
CA2807965A1 (en) 2012-03-01
AU2011293502A1 (en) 2013-02-28
US10300054B2 (en) 2019-05-28
US20210015812A1 (en) 2021-01-21
HRP20190169T1 (hr) 2019-03-22
EP2608670B1 (en) 2018-10-31
AU2017200396B2 (en) 2018-04-19
WO2012027359A1 (en) 2012-03-01
US20170119757A1 (en) 2017-05-04
EP4306164A2 (en) 2024-01-17
US20210046065A1 (en) 2021-02-18
TR201900097T4 (tr) 2019-02-21
JP5684388B2 (ja) 2015-03-11
SMT202400030T1 (it) 2024-03-13
US11793805B2 (en) 2023-10-24
AU2011293502B2 (en) 2015-03-19
EP4306164A3 (en) 2024-03-20
US11351166B2 (en) 2022-06-07
US8778960B2 (en) 2014-07-15
AU2015201907A1 (en) 2015-05-07
US20140349999A1 (en) 2014-11-27
US9517235B2 (en) 2016-12-13
HUE065427T2 (hu) 2024-05-28
SMT201900051T1 (it) 2019-02-28
ES2705726T3 (es) 2019-03-26
US11241425B2 (en) 2022-02-08
PT3446565T (pt) 2024-01-29
US20210038594A1 (en) 2021-02-11
US20240293394A1 (en) 2024-09-05
CA2807965C (en) 2016-03-15
EP3446565B1 (en) 2023-11-01
AU2015201907B2 (en) 2016-12-22
US9943514B2 (en) 2018-04-17
AU2017200396A1 (en) 2017-02-09
HUE041981T2 (hu) 2019-06-28
SI2608670T1 (sl) 2019-04-30
US9126977B2 (en) 2015-09-08
LT2608670T (lt) 2019-01-25
ES2969625T3 (es) 2024-05-21
US20220280502A1 (en) 2022-09-08
AU2018202410B2 (en) 2019-02-28
PL2608670T3 (pl) 2019-05-31
EP3446565A1 (en) 2019-02-27
US12194035B2 (en) 2025-01-14
US20160051538A1 (en) 2016-02-25
US20190307742A1 (en) 2019-10-10
HRP20240109T1 (hr) 2024-03-29
EP2608670A1 (en) 2013-07-03
CY1121128T1 (el) 2019-12-11
AU2018202410A1 (en) 2018-04-26
US20180271855A1 (en) 2018-09-27
SI3446565T1 (sl) 2024-03-29
US20120077800A1 (en) 2012-03-29
PL3446565T3 (pl) 2024-04-02
US11185541B2 (en) 2021-11-30

Similar Documents

Publication Publication Date Title
HUS1900001I1 (hu) Transztiretin expressziójának módosítása
CY2018029I2 (el) Αντι-ιικη θεραπεια
DK2569154T3 (da) Flerlags støbt legeme af træfiner
BR112013002845A2 (pt) combinação de susbtâncias ativas
IL223725B (en) Formulations of rifaximin and uses thereof
EP2595532A4 (en) IMPLANTABLE DIELECTROMETER
PL2544682T3 (pl) Fitokannabinoidy w leczeniu glejaka
ME03766B (me) Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe
DK2542189T3 (da) Håndprotese
EP2622818A4 (en) EXPANSION OF ATTENTION COMMANDS
DK3124610T3 (da) Hbv-behandling
DK2627673T3 (da) Terapier til forbedring af lungefunktionen
EP2433335A4 (en) Connector
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
FI20105639A0 (fi) Mikroselluloosan valmistus
DK2635269T3 (da) Kombinationspræparat
HUE041981T2 (hu) Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére
HRP20182057T1 (hr) Temperaturno stabilni vodeni pripravci klokintocet-meksila
DK2568829T3 (da) Pasteuriseringsanlæg med reguleret sprøjtemængde
DK2655360T3 (da) Fremgangsmåde til fremstilling af n-sulfonylsubstituerede oxindoler
DK2407155T3 (da) Formuleringer af inecalcitol
DE11739446T8 (de) Balkonkonstruktion
EP2554140A4 (en) STENT
FI20105066A0 (fi) Kasvin kasvusuoja
DK2566505T3 (da) Fremføring af kolesterylester til steroidogene væv